Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine, TBI, PBSC, and Immunosuppression for Hematopoietic Cancers
NCT00006251Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- May 2000
- Primary completion
- Sep 2005
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of fludarabine in hematologic malignancy, sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Risk of graft rejection at Day 56, Incidence of acute grade II/IV GVHD and 1 more. Started May 2000; status: completed.
02
Drugs
fludarabine
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT00006251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006251.